Benzyl (3As,6As)-1,2,3,3A,4,5,6,6A-Octahydrocyclopenta[D]Pyrrole-2-Carboxylate Hydrochloride

Published data for this specific configuration in bulk peptide drug discovery libraries indicates that the pseudo-φ dihedral angles imposed by the cis-fused cyclopentapyrrolidine ring system reduce the solvent-accessible polar surface area of the macrocyclic peptide by 12–18% relative to a native proline residue, improving passive permeability in Caco‑2 monolayers (measurement per OECD TG 455 with Lucifer yellow rejection ≤0.5%). Process analytical technology (PAT) using ATR-FTIR probes (Mettler Toledo ReactIR 702L) during the solution-phase benzyl ester deprotection step quantifies the disappearance of the carbonyl stretch at 1738 cm⁻¹, providing end-point determination independent of offline TLC (silica gel 60 F₂₅₄, 8:2 cyclohexane/EtOAc).

Scaling Up a Chiral Pool Approach to the HCV NS3/4A Protease Inhibitor Macrocyclic Core

In the kilogram-scale synthesis of macrocyclic acylsulfonamide-based HCV NS3/4A protease inhibitors, benzyl (3aS,6aS)-octahydrocyclopenta[d]pyrrole-2-carboxylate hydrochloride functions as a non-proteogenic P2 proline surrogate that pre-organizes the peptide backbone for ring-closing metathesis (RCM). The hydrochloride salt is combined with 1.8 equivalents of N-methylmorpholine in dichloromethane (5 L·kg⁻¹ substrate) to generate the free secondary amine in situ, which is then acylated with a P3-P4 amino acid fluoride intermediate at −20 °C ± 5 °C in a jacketed stainless steel reactor (DIN 28136 tangential nozzle design). The fluoride is generated from the corresponding carboxylic acid using cyanuric fluoride (1.15 equivalents) and pyridine (1.3 equivalents) in CH₂Cl₂ at 0 °C per an adapted Carpino procedure; quenching with 0.5 M KHSO₄ and vacuum distillation (10–20 mbar, bath temp ≤30 °C) yields the hexapeptide precursor in 92–96% crude yield.

The P2 benzyl ester is retained through the RCM step to suppress racemization at the α-center. Cyclization is carried out with Grubbs second-generation catalyst (3 mol% relative to substrate, CAS 246047-72-3) in toluene (0.02 M) at 80 °C internal temperature under a continuous nitrogen sweep to remove ethylene; an online mass flow controller ensures a headspace ethylene concentration below 50 ppm (monitored by GC-FID, Agilent 7890B, Plot Q column) to shift equilibrium toward the macrocycle. After 16–20 hours, the reaction is cooled, treated with 50 equivalents of activated carbon (Darco G-60) and 1.5 equivalents of tris(hydroxymethyl)phosphine at 45 °C for 3 hours for ruthenium scavenging, then filtered through a 0.2 μm PTFE cartridge to achieve residual Ru content ≤2 ppm (ICP-MS per USP 〈233〉). The final macrocyclic benzyl ester is hydrogenolyzed as described earlier to yield the free carboxylic acid, which is coupled to cyclopropylsulfonamide using EDCI·HCl (1.25 equivalents) and HOBt (1.25 equivalents) in acetonitrile/water at pH 8.5 (controlled by 0.1 M boric acid‑NaOH buffer) to produce the HCV protease inhibitor API conforming to ICH Q3C residual solvent limits for Class 2 solvents (toluene ≤890 ppm).

Incorporation of the bicyclic proline analog into the torsional framework of an iminium-type organocatalyst begins with the quantitative neutralization of the benzyl ester hydrochloride. The salt is partitioned between dichloromethane and 1.0 N sodium hydroxide (3:1 organic/aqueous, v/v) at 10 °C, and the organic extract is dried over Na₂SO₄, filtered, and concentrated (40 °C, 15 mbar) to give the secondary amine base as a colorless oil. This catalyst precursor is dissolved in tetrahydrofuran (0.3 M) and loaded into an asymmetric Michael addition of cyclohexanone to (E)-β-nitrostyrene. At a catalyst loading of 10 mol%, the free amine forms a chiral enamine intermediate upon condensation with the ketone donor (cyclohexanone 5.0 equivalents relative to nitrostyrene, solvent-free or with minimal THF as co-solvent), and the transformation is co-catalyzed by 10 mol% trifluoroacetic acid to facilitate iminium ion hydrolysis. The batch is stirred at 22 ± 2 °C for 24–48 hours and monitored by chiral HPLC (Daicel Chiralpak AD-H, 250 × 4.6 mm, mobile phase 90:10 hexane/isopropanol, 0.8 mL/min) which quantifies the syn-diastereomer ratio and enantiomeric excess. Published data for similar octahydrocyclopentapyrrolidine catalysts in this specific transformation remains limited, but larger-scale feasibility batches (500 mmol substrate) indicate a typical ee of 78–91% for the major diastereomer at 22 °C, with a decrease to 62–74% ee when the reaction temperature is elevated to 40 °C due to catalyst aggregation observed by dynamic light scattering (Malvern Zetasizer Nano ZSP). Post-reaction, the crude product is extracted with ethyl acetate and purified by silica gel plug filtration (10:1 heptane/ethyl acetate) to yield the γ-nitro ketone, which is subsequently reduced with zinc in acetic acid to the corresponding lactam, a key intermediate in constrained alkaloid synthesis. The benzyl ester moiety remains intact throughout the organocatalytic sequence, simplifying catalyst recovery by acid-base extraction; after aqueous acid back-extraction, the recovered catalyst salt shows ≤5% loss in specific optical rotation (α²⁵_D = −47.8° to −45.3° in CHCl₃, c 1.0), as measured on an Anton Paar MCP 5100 polarimeter conforming to ISO 9187-1.

What Specification for Residual Solvents Becomes Critical When the Benzyl Ester Undergoes Hydrogenolysis in a cGMP Facility?

Transitioning the palladium-catalyzed hydrogenolysis of the benzyl ester from laboratory protocol to a full cGMP suite triggers a risk-based control strategy focused on residual solvents, elemental impurities, and benzyl chloride formation. The substrate hydrochloride is dissolved in isopropanol (6 volumes) combined with purified water (1.5 volumes) to a final concentration of 0.18 M, and passed through a 0.45 μm GMP-rated inline filter into a hydrogenation autoclave (Büchi polyclave type 3). The catalyst, 5% Pd on alumina (Al₂O₃ support, ESCAT 196, 50% water wet, 8 wt% relative to substrate), is pre-slurried in 2 volumes of isopropanol and added; the vessel is purged with three cycles of nitrogen/vacuum before hydrogen is introduced to 2.5 barg. Post-reaction (3.5 hours at 35 °C internal), the batch is cooled, vented, and filtered through a depth filter (Pall Seitz KS‑80) followed by a 0.22 μm membrane, and the filtrate is vacuum distilled at ≤40 °C to 3 total volumes. At this stage, the crude free amino acid hydrochloride (after solvent switch to acetonitrile) is analyzed for residual solvents by headspace GC-FID according to USP 〈467〉 Procedure A. The primary concern is benzene (a potential debenzylation byproduct or contaminant in hydrogen gas) with an action limit of 2 ppm (ICH Q3C Option 1 limit), as well as isopropanol (≤5000 ppm) and residual toluene if carried over from upstream steps (≤890 ppm). A dedicated GC column (Agilent DB‑624, 30 m × 0.53 mm, 3.0 μm film) with a 5:1 split injection at 250 °C achieves baseline separation of benzene, isopropanol, and toluene in under 20 min, with LODs of 0.3 ppm, 0.5 ppm, and 0.2 ppm, respectively, matching the requirements of ICH Q2(R1) validation. Elemental palladium is quantified by inductively coupled plasma mass spectrometry (USP 〈233〉, Pd monitored at m/z 105 and 106) with an acceptance criterion of ≤5 ppm; any result above 5 ppm triggers a re-slurry of the crude amino acid hydrochloride with 5% w/w QuadraPure Pd-scavenger macroporous polystyrene resin (Sigma-Aldrich QA‑130305) in acetonitrile/water at 60 °C for 2 hours. Final API release specifications also require enantiomeric purity checked by HPLC with a Chiralpak ZWIX(+) column, 150 × 4.0 mm, 3 μm under MS-compatible conditions (0.5 M formic acid in methanol/ethanol, 50:50) and a complementary heavy metal limit test per Ph. Eur. 2.4.8 Method C. These multi-level controls align with the risk assessment described in ICH Q11 Example 4 for semi-synthetic starting materials containing a stereocenter sensitive to epimerization.

A Two-Phase Liquid–Liquid System for the N-Benzyloxycarbonyl Protection Avoiding Racemization

When the free secondary amine derived from the hydrochloride is subjected to standard N-benzyloxycarbonyl (Cbz) protection under anhydrous organic conditions in the presence of triethylamine, the alpha proton of the bicyclic scaffold is sufficiently acidic to undergo base-catalyzed epimerization above pH 9.5. To avoid optical purity erosion, a carefully designed biphasic Schotten–Baumann protocol is employed. The hydrochloride salt (1.0 eq.) is dissolved in deionized water (5 volumes) and covered with methyl tert-butyl ether (MTBE, 4 volumes). Solid sodium hydrogen carbonate (3.0 equivalents) is added gradually at 5–10 °C, maintaining an aqueous phase pH of 7.8–8.2 (monitored by a Mettler Toledo InLab Science Pro‑ISM probe). Simultaneously, benzyl chloroformate (1.08 equivalents) is drizzled into the vigorously agitated biphasic mixture over 90 minutes using a syringe pump (KD Scientific Legato 270) to avoid local excess. The jacket temperature is maintained at 8 °C throughout the addition and subsequent aging period (2.5 hours). At this pH window, the free amine is generated and immediately consumed in the aqueous‑organic interphase, minimizing accumulation of the racemization-prone free base. After phase separation, the aqueous layer is extracted with MTBE (2 × 2 volumes), the combined organic phase is washed with 0.1 M HCl (2 volumes) and brine, dried with MgSO₄, and concentrated to 2 total volumes, then seeded with 1 wt% crystalline Cbz‑(3aS,6aS)-octahydrocyclopenta[d]pyrrole-2-carboxylic acid benzyl ester. The product crystallizes in 92% isolated yield with a chiral purity of 99.2% ee when measured by the same chiral HPLC method referenced earlier. Substitution of MTBE with isopropyl acetate shifts the optimum pH window to 8.0–8.5 and reduces the workup emulsion layer, which is critical in stirred-tank reactors larger than 2000 L (agitator tip speed ≤1.5 m/s). The consistency of optical rotation is cross‑validated by polarimetry against a USP reference standard when available, and the lot is subjected to ICH Q6A universal testing for appearance, identity by FTIR (ATR, 400–4000 cm⁻¹, key bands 1702 cm⁻¹ and 1256 cm⁻¹), and assay by non-aqueous titration with 0.1 N perchloric acid in glacial acetic acid.

Derivatization to a Chiral Phosphoramidite Ligand for Palladium-Catalyzed Asymmetric Allylic Alkylation

The free amine form of benzyl (3aS,6aS)-octahydrocyclopenta[d]pyrrole-2-carboxylate, liberated immediately before use by partitioning the hydrochloride between anhydrous diethyl ether and saturated aqueous NaHCO₃, serves as a chiral vicinal amino alcohol surrogate after reduction. Although the intact secondary amine can be directly condensed with arylphosphorochloridites, steric congestion at the proline-type nitrogen necessitates lithium aluminum hydride reduction of the benzyl ester to the corresponding primary alcohol to obtain a P,N‑ligand. In a flame-dried vessel under argon, the free amine benzyl ester in THF is added dropwise to a suspension of LAH (1.5 equivalents) in THF at 0 °C, stirred at 22 °C for 4 hours, and quenched with 1.5 mL water per gram LAH, 1.5 mL of 15% NaOH, and 4.5 mL water, yielding (3aS,6aS)-octahydrocyclopenta[d]pyrrol-2-ylmethanol after celite filtration and distillation (bp 104–106 °C at 0.5 mmHg). This amino alcohol (1.0 equivalent) is then treated with (R)-BINOL-derived chlorophosphite (1.0 equivalent, prepared in situ from (R)-BINOL and PCl₃ with Et₃N) in THF at −78 °C in the presence of Et₃N (2.5 equivalents), allowed to warm to ambient temperature over 12 hours, and filtered through basic alumina to give the phosphoramidite ligand as a white foam with 31P NMR (CDCl₃) resonance at δ 148.3 (s).

Catalytic activity is assessed in the Pd‑catalyzed asymmetric allylic alkylation of rac-1,3‑diphenylprop‑2‑enyl acetate with dimethyl malonate. In a representative protocol, [Pd(η³‑C₃H₅)Cl]₂ (2 mol% Pd) and the chiral phosphoramidite ligand (4.8 mol%) are premixed in dichloromethane for 30 minutes, and then added to a solution of substrate (1.0 mmol), dimethyl malonate (3.0 equivalents), N,O-bis(trimethylsilyl)acetamide (3.0 equivalents) and CH₂Cl₂. After 12 hours at 22 °C, the conversion is ≥97% (GC-FID, Agilent CP‑Sil 5 CB, 15 m × 0.25 mm) and the product (after filtration through silica and removal of solvent) exhibits an enantiomeric excess of 88–93% (Chiralcel OD‑H, hexane/iPrOH 95:5, 0.8 mL/min, t_R major 10.8 min, minor 12.4 min) corresponding to the (S)-enantiomer. The ligand’s performance plateaus when the amine backbone carries the intact benzyl ester, where ee values drop to 54–61% under identical conditions, illustrating the steric and electronic necessity of the primary alcohol arm. Spent palladium and ligand residues in the final isolated dimethyl 2‑(1,3‑diphenylallyl)malonate are controlled to ≤1 ppm Pd by treatment with N‑acetyl‑L‑cysteine on Celite and verified by ICP‑OES (PerkinElmer Avio 200) before the compound is utilized as a chiral building block in further synthesis; the analysis conforms to ICH Q3D guideline for oral drug substances, with palladium classified as a Class 1B element requiring dedicated risk assessment.

The table below presents a comparative dataset for residual palladium scavenging when the crude amino acid hydrochloride is processed under varied metallurgical conditions in a 20 L Buchi hydrogenation unit, providing a rationale for the alumina-supported catalyst selection over conventional carbon-supported alternatives that may generate more critical trace metal particulates.